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TO THE EDITOR
Impetigo herpetiformis (IH) is a rare
pustular dermatosis that typically occurs
in pregnant women sporadically with
unknown etiology (Sauer and Geha,
1961). Early diagnosis is essential, as
IH is life-threatening and is associated
with placental insufficiency and
electrolyte abnormalities. IH appears to
have the same clinical and histologic
appearance as generalized pustular
psoriasis (GPP), which is also a rare
severe episodic pustular dermatosis
that occurs repeatedly in both sexes at
any age. However, some researchers
have regarded IH as an entity distinct
from GPP, because some patients are
affected by IH only in the gestational
period (Lotem et al., 1989). Recently,
we reported that the majority of GPP
that is not accompanied by psoriasis
vulgaris (PV; GPP alone) is caused by
homozygous or compound hetero-
zygous mutations of IL36RN, which
encodes IL-36 receptor antagonist (IL-
36RN), although only a small number of
cases with GPP preceding or accomp-
anied by PV (GPP with PV) were found
to have IL36RN mutations (Sugiura
et al., 2013). Very recently, we
reported that CARD14 c.526G4C is a
significant risk factor for GPP with PV,
but not for GPP alone in the Japanese
cohort, which further supports the idea
that GPP with PV differs genetically
from GPP alone (Sugiura et al., 2014a).
However, to our knowledge, there have
been no reports of IH with IL36RN
mutations. Here we report two cases of
IH with homozygous and heterozygous
IL36RN mutations.
Cases 1 and 2 were a 23-year-old
woman and a 28-year-old Japanese
woman who were admitted to our
hospitals for pustular lesions in the
29th week and the 20th week of their
first pregnancies, respectively (Figure 1a
and b). There was no family history of
GPP, no IH, and no consanguinity in
their families. Case 1 had no previous
history of GPP. Her pustular lesions had
begun to develop at the 21st week of
pregnancy, and she had been hospita-
lized in a maternity hospital. Oral pre-
dnisolone at a dose of 15 mg per day
had been administered, but the erup-
tions had persisted. A skin biopsy from a
pustular eruption on the trunk revealed
a spongiform pustule of Kogoj in the
epidermis consistent with IH (Figure 1c).
Case 2 had suffered from GPP from the
age of 8 to 18 years. Skin biopsies from
pustular eruptions on the trunk revealed
spongiform pustules of Kogoj in the
epidermis at the age of 8 and 28 years
(Figure 1d). She had been admitted to
hospitals four times for GPP flare-ups.
She had been treated with cyclosporine
or etretinate. In the ten years leading up
to her pregnancy, her GPP had been in
remission without any treatment. Both
cases had erythema with pustules over
the whole body and fever of over 38 1C.
Blood examinations from Cases 1
and 2, respectively, revealed white
blood cell counts of 12,000ml1 and
21,170ml1, and C-reactive protein
concentrations of 6.5 and 14.9 mg dl1
(normal range:o0.3 mg dl 1). Bacterial
cultures of the pustules were negative.
Thus, Cases 1 and 2 were, respectively,
diagnosed as having IH and IH with a
previous history of GPP.
Following ethical approval, written
informed consent was obtained in com-
pliance with the Declaration of Helsinki
Principles. The entire coding regions of
IL36RN including the exon/intron
boundaries were sequenced using geno-
mic DNA samples from the patients.
Case 1 had the homozygous mutation
c.115þ6T4C, which was proven to
result in p.Arg10ArgfsX1 in IL36RN
by us previously, and Case 2 had
the heterozygous mutation c.28C4T
(p.Arg10X) in IL36RN. Both of these
are GPP-causing founder mutations in
the Japanese cohort (Sugiura et al.,
2013, 2014b; Figure 1e and f,
and Figure 2). A search for a second
IL36RN mutation in all intron and
putative promoter regions in Case 2
revealed no other IL36RN mutations
(Supplementary Figure S1 online and
Supplementary Table S1 online). How-
ever, there is still the possibility of a
second unidentified IL36RN mutation in
Case 2.
More than 10 cases of GPP with
heterozygous IL36RN mutations have
been reported (Capon, 2013; Korber
et al., 2013; Li et al., 2013; Setta-
Kaffetzi et al., 2013; Sugiura et al.,
2013). Moreover, in some patients,
heterozygous IL36RN mutations are
associated with palmoplantar pustu-
losis, a type of pustular psoriasis, and
acute generalized exanthematous
pustulosis, a severe cutaneous drug
reaction (Navarini et al., 2013; Setta-
Kaffetzi et al., 2013). IL-36 is absent in
normal skin but is induced by inflamma-
tory cytokines such as tumor necrosis
factor-a, IL-17A, and IL-22 (Carrier
et al., 2011). When functional IL-36RN
is absent or underproduced, over-
expressed IL-36 can induce neutrophil-
rich infiltration. Tumor necrosis factor-a
is often elevated in the blood of
pregnant women, whereby it induces
various serious diseases (Mallmann
et al., 1991). As for skin diseases,
tumor necrosis factor-a sometimes
causes exacerbation of PV lesions in
pregnant women (Puig et al., 2010).
Hence, it is very likely that a pregnant
woman who has the IL36RN mutation
occasionally cannot produce enough
IL-36RN to adequately antagonize IL-36
excessively induced by inflammatory
cytokines, and this imbalance results
in IH.
After longstanding controversy over
whether IH is an independent diseaseAccepted article preview online 9 April 2014; published online 1 May 2014
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entity from GPP, today there is the
consensus that IH is not a distinct entity
but is identical to GPP, i.e., IH is GPP
occurring during pregnancy (Lotem
et al., 1989; Robinson et al., 2012).
However, there have been no reports
with experimental or genetic evidence
to bolster the assertion that IH and GPP
are identical diseases. This report clearly
shows IH patients with homozygous or
heterozygous IL36RN mutations. Case 1
was affected with IH only once in the
gestational period. In this context, the
present case suggests that IH and GPP,
especially GPP alone, are identical
diseases caused by IL36RN mutations.
Future study should elucidate the
proportion of IH cases that are IL36RN
negative; however, given that the
majority of GPP alone is associated
with IL36RN mutations, we consider
that mutation analysis of IL36RN is a
very promising method for the
prediction of IH risk to prevent
subsequent serious complications in
the patient and the fetus.
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Figure 1. Clinical features, pathological findings of pustules, and mutation analysis of IL36RN in the
patients. The clinical features of Cases 1 and 2 (a, b) are shown. Pustules on background erythema are seen
on the trunk and arms. The pathology of the pustules is indicated for Cases 1 and 2 (c, d). Spongiosis
of Kogoj and acanthosis are observed in the epidermis of the pustular erythematous lesions on the trunks.
Scale bar¼ 50mm for c and 100mm for d. Direct sequencing reveals the homozygous mutation
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Figure 2. The second structure of IL-36RN and location of all IL36RN mutations ever reported in
generalized pustular psoriasis (GPP) and impetigo herpetiformis (IH). All IL36RN mutations ever reported
in GPP and IH (including in the present report) are shown (Kanazawa et al., 2013). The blue characters
indicate truncating mutations, and the black characters indicate missense mutations. Red lines show
critical residues that mediate receptor interaction, such as Tyr89, Glu94, and Lys96 of IL36-RN (Sugiura
et al., 2013).
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